

Sample page layout for RF QUARTERLY and monthly peer-reviewed articles

[Article title] Lorem ipsum dolor sit EMA, consectetur adipiscing elit

[Author name(s)]

Author One, PhD, RAC

Author Two, PharmD, MBA

Author Three, BSc, RAC

Abstract

Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Keywords – combination products, cross-labeling, drug delivery

[Level 1 subhead] Introduction

Accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo. Nemo enim ipsam voluptatem quia voluptas ipsam

... At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati¹ cupiditate fuga.

Level 1 subhead

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi consequat.

Level 2 subhead

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo (**Table 1**) inventore veritatis et quasi architecto beatae.

Table 1. Regulatory starting materials accepted by the EMA in the approved MAA²

RSMs accepted by EMA	Change incurred from NDA to MAA review	No. of chemical conversion steps	No. of isolated intermediates	RSM suppliers
RSM 1	Yes, reduced to 1 supplier	5 ^a	5	Single
RSM 2	Yes, reduced to 1 supplier	4	1	Single
RSM 3	Yes, redefined from US RSM 3, which is now an intermediate in EU	4	2 ^b	Single
RSM 4	Yes, redefined from US RSM 3, which is now an intermediate in EU	4	2	Multiple

EMA, European Medicines Agency; **MAA**, marketing authorization application [EU]; **NDA**, new drug application [US]; **RSM**, regulatory starting material.


^aSed do eiusmod tempor incididunt ut labore. ^bVoluptates repudiandae sint et molestiae non recusandae.

Level 2 subhead

Sample page layout for RF QUARTERLY and monthly peer-reviewed articles

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti (Figure 1). Corrupti quos dolores et quas molestias excepturi sint² occaecati cupiditate.

Figure 1. Sources of elemental impurities



Source: xxx

Level 3 subhead. Temporibus autem quibusdam et aut officiis debitis aut rerum necessitatibus saepe eveniet ut et voluptates repudiandae sint et molestiae non recusandae.

Level 3 subhead. Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi consequat voluptatem quia voluptas sit aspernatur aut odit aut fugit.

Level 2 subhead

At vero eos et accusamus et iusto odio dignissimos ducimus qui blanditiis praesentium voluptatum deleniti atque corrupti quos dolores et quas molestias excepturi sint occaecati cupiditate.

Level 1 subhead

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua^{3,4}

- Doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo inventore Veritatis;
- Nemo enim ipsam voluptatem quia voluptas sit aspernatur aut odit aut fugit:
 - Sed quia consequuntur magni,
 - Dolores eos qui ratione voluptatem,
 - Sequi nesciunt;
- Neque porro quisquam est, qui dolorem ipsum quia; and/or
- Dolor sit amet, consectetur, adipisci velit, sed quia non.

Numquam eius modi tempora incidunt ut labore et dolore magnam aliquam quaerat voluptatem.⁵

[Level 1 subhead] Conclusion

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam, eaque ipsa quae ab illo veritatis et quasi architecto beatae vitae dicta.

Sample page layout for RF QUARTERLY and monthly peer-reviewed articles

[11 ptCalibri bold] Abbreviations

API, active pharmaceutical ingredient; **CHMP**, Committee for Medicinal Products for Human Use; **CMC**, chemistry, manufacturing, and controls; **ICH**, International Council for Harmonisation.

[11 ptCalibri bold] About the authors

Author One, PhD, RAC, is the director of regulatory affairs at xxx. She has more than 18 years' experience in regulatory affairs of healthcare products, with a focus on the CMC aspects of small molecules. **Lastname** has a bachelor of science degree in chemistry from the University of xxx, a doctorate degree in molecular and industrial biotechnology from the University of xxx, and holds the RAPS Regulatory Affairs Certification. She can be reached at **contact email**.

Author Two, PharmD, MBA, is the xxx at xxx ... can be reached at **contact email**.

Author Three, BSc, RAC, is the xxx at xxx ... can be reached at **contact email**.

Disclaimer This article is solely attributed to the authors and is not associated with their respective employment with Company A and Company B. The views expressed in the article are their own and do not represent those of their respective employers.

Acknowledgment The authors thank xxx and xxx for editorial support and feedback during the development stages of this article.

Citation [Editorial team will add this information]

References

All references were verified on xx Month 2024. [Editorial team will add this information]

1. International Council for Harmonisation. ICH Q3A(R2) Impurities in new drug substances [guidance]. Current as of 25 October 2006. Accessed 29 March 2023. <https://database.ich.org/sites/default/files/Q3A%28R2%29%20Guideline.pdf>
2. Basak AK, et al. Pharmaceutical impurities: Regulatory perspective for abbreviated new drug applications. *Adv Drug Deliv Rev*. Published online 15 November 2006. Accessed 30 March 2023. <https://doi.org/10.1016/j.addr.2006.10.010>
3. European Medicines Agency. European Medicines Regulatory Network approach for the implementation of the CHMP Opinion pursuant to Article 5(3) of Regulation (EC) No 726/2004 for nitrosamine impurities in human medicines. Dated 22 February 2021. Accessed 21 April 2023. https://www.ema.europa.eu/en/documents/referral/european-medicines-regulatory-network-approach-implementation-chmp-opinion-pursuant-article-53-regulation-ec-no-726-2004-nitrosamine-impurities-human-medicines_en.pdf
4. Food and Drug Administration. Control of nitrosamine impurities in human drugs [guidance]. Dated February 2021. Accessed 31 March 2023. <https://www.fda.gov/media/141720/download>
5. US Pharmacopeia. USP Chapter <1086> Impurities in drug substances and drug products. United States Pharmacopeia: Rockville, MD. Verified 19 April 2023.